Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicorandil and Verapamil for Myocardial Injury in PCI
NCT05399576Phase 2Unknown
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- May 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nicorandil and verapamil in coronary artery disease (CAD) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Incidence of periprocedural myocardial injury and infarction at 24 hours and Index of Microcirculatory Resistance at 24 hours. Status: unknown.
02
Drugs
nicorandilverapamil
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT05399576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05399576.